Albane Degrassat-Théas

Temporary Authorization for Use: Does the French Patient Access Programme for Unlicensed Medicines Impact Market Access After Formal Licensing?

Albane Degrassat-Théas, Pascal Paubel, O. Parent de Curzon et al. · PharmacoEconomics · 2013 · 22 citations

Temporary Authorization, Formal Licensing, Health Economics +9

The “Temporary Recommendations for Use”: A dual-purpose regulatory framework for off-label drug use in France

Albane Degrassat-Théas, François C. Bocquet, M. Sinègre et al. · Health Policy · 2015 · 22 citations · Full text

Preclinical Therapeutics, Substance Use, Rtu Framework +25

The new regulatory tools of the 2016 Health Law to fight drug shortages in France

François C. Bocquet, Albane Degrassat-Théas, Jérôme Peigné et al. · Health Policy · 2017 · 21 citations · Full text

New Regulatory Tools, Drug Policy, Health Politics +16

What About Offering a Financial Incentive Directly to Clinical Units to Encourage the Use of Biosimilars? Results of a Two-Year National Experiment in France

Marion Tano, Pascal Paubel, M. Ribault et al. · Applied Health Economics and Health Policy · 2023 · 15 citations · Full text

Financial Incentive Directly, Health Economics, Health Policy +12

Hospital Reimbursement Price Cap for Cancer Drugs

Albane Degrassat-Théas, M. Bensadon, C. Rieu et al. · PharmacoEconomics · 2012 · 12 citations

Health Economics, Medicine, Health Care Reimbursement +10